3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
209
Lung Neoplasms
80
Breast Neoplasms
68
Triple Negative Breast Neoplasms
67
Ovarian Neoplasms
57
Squamous Cell Carcinoma of Head and Neck
50
Small Cell Lung Carcinoma
44
Fallopian Tube Neoplasms
38
Endometrial Neoplasms
33
Neoplasms
30
Parkinson Disease 4, Autosomal Dominant Lewy Body
28
Neoplasm Metastasis
28
Head and Neck Neoplasms
24
Prostatic Neoplasms
20
Carcinoma
18
Esophageal Neoplasms
17
Urinary Bladder Neoplasms
16
Colorectal Neoplasms
16
Uterine Cervical Neoplasms
15
Oropharyngeal Neoplasms
14
Carcinoma, Transitional Cell
14
Carcinoma, Squamous Cell
14
Esophageal Squamous Cell Carcinoma
13
Brain Neoplasms
12
Stomach Neoplasms
10
Pancreatic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Mouth Neoplasms
9
Laryngeal Neoplasms
9
Carcinoma, Ovarian Epithelial
9
Interventions
pembrolizumab
2
Pemetrexed
1
MRX-2843
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Carboplatin
×
1 year
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled